Markers for cancer

A method for determining whether a human subject either has developed or is predisposed for colorectal cancer, comprising:

• a) determining the methylation level, the number of methylated CpG sites or the methylation state of CpG sites in a nucleic acid sequence in the promoter region, first exon or intron, of CNRIP1 in a biological sample selected from blood, stool, a section or biopsy of a neoplasm in the colon or rectum or a portion of the surrounding normal tissue, obtained from said human subject, and
• b) comparing the methylation level, the number of methylated CpG sites or the methylation state of CpG sites in the nucleic acid sequence in the promoter region, first exon or intron, of CNRIP1 in the biological sample, obtained from said human subject, with the methylation level, the number of methylated CpG sites or the methylation state of CpG sites in the nucleic acid sequence in the promoter region, first exon or intron, of CNRIP1 in a biological sample, obtained from a healthy human, wherein a higher methylation level, the number of methylated CpG sites or the methylation state of CpG sites in the nucleic acid sequence in the promoter region, first exon or intron, of CNRIP1 in the sample, obtained from said human subject, as compared to the methylation level, the number of methylated CpG sites or the methylation state of CpG sites in the nucleic acid sequence in the promoter region, first exon or intron, of CNRIP1 in the biological sample, obtained from a healthy human, indicates that said human subject either has developed or is predisposed for developing colorectal cancer.